Holen Sie sich die Stockscreener-App
2.90
0.69%
0.02
Handel nachbörslich:
2.90
Schlusskurs vom Vortag:
$2.88
Offen:
$2.76
24-Stunden-Volumen:
282.04K
Relative Volume:
0.84
Marktkapitalisierung:
$248.02M
Einnahmen:
$351.37M
Nettoeinkommen (Verlust:
$-174.01M
KGV:
-1.401
EPS:
-2.07
Netto-Cashflow:
$-126.94M
1W Leistung:
-3.97%
1M Leistung:
+0.00%
6M Leistung:
-12.91%
1J Leistung:
-25.64%
1-Tages-Spanne:
$2.76
$3.01
1-Wochen-Bereich:
$2.76
$3.04
52-Wochen-Spanne:
$2.75
$4.145
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
Firmenname
Atea Pharmaceuticals Inc
Sektor
Branche
Telefon
857-204-8109
Adresse
225 FRANKLIN STREET, BOSTON
Vergleichen Sie AVIR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
2.90 | 248.02M | 351.37M | -174.01M | -126.94M | -2.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-13 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-08-10 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-01-06 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-18 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-10-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-25 | Eingeleitet | Evercore ISI | Outperform |
| 2020-11-24 | Eingeleitet | JP Morgan | Overweight |
| 2020-11-24 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-11-24 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Atea Pharmaceuticals Inc Aktie (AVIR) Neueste Nachrichten
Atea Pharmaceuticals board nominee withdrawal ahead of 2025 meeting By Investing.com - Investing.com South Africa
Atea Pharmaceuticals board nominee withdrawal ahead of 2025 meeting - Investing.com
Driver Notifies Atea Pharmaceuticals of Withdrawal of Notice of Nomination - The Manila Times
Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace
Charles Schwab Investment Management Inc. Boosts Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals takes steps to boost shareholder value By Investing.com - Investing.com South Africa
Atea Pharmaceuticals takes steps to boost shareholder value - Investing.com
Atea Pharma Reviewing Strategic Opportunities After Cutting 25% of Jobs - MarketWatch
Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder Value - GlobeNewswire
Atea's Bold Restructuring: $15M Cost Savings Plan and Strategic Review Unveiled - Stock Titan
Atea Shareholder Seeks Board Change, Plans to Nominate Directors at 2025 Annual Meeting - Marketscreener.com
The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors - MarketScreener
Connor Clark & Lunn Investment Management Ltd. Raises Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals Issues Statement Regarding Director Nominations - GlobeNewswire
Atea Pharmaceuticals receives notice of director nominations from Bradley Radoff -March 21, 2025 at 05:58 pm EDT - MarketScreener
Major Shake-up Looms: Activist Investor Challenges Atea Pharmaceuticals Board Control - StockTitan
Atea Pharmaceuticals, Inc. (AVIR): A Bull Case Theory - Insider Monkey
Atea Pharmaceuticals Announces Presentation of - GlobeNewswire
Major Breakthrough: Atea's New Hepatitis C Drug Enters Final Testing with Shorter Treatment Time - StockTitan
Earnings call transcript: Atea Pharmaceuticals Q4 2024 results weigh on stock - Investing.com Australia
What is William Blair’s Forecast for AVIR Q1 Earnings? - Defense World
William Blair Reaffirms “Outperform” Rating for Atea Pharmaceuticals (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals Faces Challenges Amid Workforce Reductions and Cost-Cutting Efforts - MSN
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q4 2024 Earnings Call Transcript - Insider Monkey
BML Capital Management LLC Has $25.49 Million Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - MarketBeat
Atea Pharmaceuticals’ Promising Earnings Call Highlights - TipRanks
Atea Pharma Cuts Workforce By 25%, Expects $15 Million In Cost Savings, Plans Phase 3 Hepatitis C Trial - Benzinga
Atea Pharmaceuticals Advances HCV Program with FDA Approval - TipRanks
Atea Pharmaceuticals Cuts Workforce by 25% - MarketWatch
Atea Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Atea Pharmaceuticals reports Q4 EPS (40c), consensus (29c) - TipRanks
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides - The Bakersfield Californian
Can Atea's 98% Effective HCV Drug Reshape the $3B Market? FDA Says Yes to Phase 3 - StockTitan
Atea Pharmaceuticals (AVIR) Expected to Announce Quarterly Earnings on Thursday - Defense World
AVIRAtea Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 6, 2025 - GlobeNewswire
Atea Pharmaceuticals to Host Conference Call on Q4 and Full Year 2024 Financial Results - Nasdaq
When Will Atea Pharmaceuticals Reveal Its Antiviral Pipeline Progress? Key Date for Biotech Investors - StockTitan
Atea Pharmaceuticals Appoints Arthur Kirsch as Class I Director Amid Voting Agreement Disclosure - Defense World
Atea Pharmaceuticals appoints Arthur Kirsch to Board By Investing.com - Investing.com Canada
Atea Pharmaceuticals Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
Atea Pharmaceuticals Appoints Arthur Kirsch as Director - TipRanks
Atea Pharmaceuticals appoints new board member By Investing.com - Investing.com Canada
Atea Pharmaceuticals appoints new board member - Investing.com India
Atea Pharmaceuticals appoints Arthur Kirsch to Board - Investing.com India
Finanzdaten der Atea Pharmaceuticals Inc-Aktie (AVIR)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.23%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):